Dermira Inc (DERM.OQ)
DERM.OQ on NASDAQ Stock Exchange Global Select Market
8.92USD
20 Apr 2018
8.92USD
20 Apr 2018
Change (% chg)
$0.31 (+3.60%)
$0.31 (+3.60%)
Prev Close
$8.61
$8.61
Open
$8.60
$8.60
Day's High
$8.92
$8.92
Day's Low
$8.56
$8.56
Volume
215,366
215,366
Avg. Vol
331,072
331,072
52-wk High
$34.45
$34.45
52-wk Low
$6.99
$6.99
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
| Name | Age | Since | Current Position |
|---|---|---|---|
Thomas Wiggans |
65 | 2014 | Chairman of the Board, Chief Executive Officer, Co-Founder |
Christopher Griffith |
40 | 2017 | Senior Vice President - Corporate Development and Strategy, Founder |
Luis Pena |
54 | 2016 | Co-Founder, Chief Development Officer |
Andrew Guggenhime |
48 | 2017 | Chief Financial Officer, Chief Operating Officer |
Christopher Horan |
2018 | Chief Technical Operations Officer |
- Dermira to abandon acne drug, shares crater
- UPDATE 2-Dermira to abandon acne drug, shares crater
- Dermira abandons acne drug
- BRIEF-Dermira's Two Phase 3 Trials Evaluating Olumacostat Glasaretil In Patients With Acne Vulgaris Did Not Meet Co-Primary Endpoints
- BRIEF-Dermira Qtrly Loss Per Share $1.34